Accord Files Stelara Rival With EMA
Intas Unit Submits Application For Dong-A/Meiji Seika Pharma Ustekinumab Biosimilar
Intas has announced that its Accord Healthcare unit has filed in Europe the DMB-3115 biosimilar ustekinumab candidate licensed from Japan’s Meiji Seika Pharma and Korea’s Dong-A.
